L'intérêt à découvert pour AtriCure donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de AtriCure. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

AtriCure (NASDAQ:ATRC) Stock, Rapport sur les intérêts à découvert

AtriCure

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

AtriCure Inc

<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Atricure.com&amp;esheet=54113283&amp;newsitemid=20240827359775&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=18e0f9147650ec01358e204c7f81ae96">AtriCure, Inc.</a> ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=http%3A%2F%2Fir.atricure.com%2Fphoenix.zhtml%3Fc%3D189981%26p%3Dirol-irhome&amp;,%20esheet=54113283&amp;,%20newsitemid=20240827359775&amp;,%20lan=en-US&amp;,%20anchor=Nasdaq%3A+ATRC&amp;,%20index=2&amp;,%20NASDAQ:%3Ca%20class=">ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip&#xAE; FLEX-Mini&#x2122; device, which recently received 510(k) clearance. The AtriClip FLEX-Mini sets a new standard as the smallest profile surgical LAA device on the market and builds upon the proven technology of AtriCure's AtriClip platform, with ease of use and design simplicity that offers enhanced access and increased visibility for physicians.</p>


Biotech

News

General

ATRC

AtriCure Reports First Patient Has Been Treated With The Revolutionary AtriClip FLEX-Mini Device

<p><strong>AtriCure, Inc.&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atrc#NASDAQ">ATRC</a>) recently announced the receipt of an expanded indication for the AtriClip&nbsp;in CE-marked countries in&nbsp;Europe. The product is now indicated for use in patients at high risk of thromboembolism for whom left atrial appendage (LAA) exclusion is warranted.</p>
<p>The European Commission&#39;s expanded indication is based on AtriCure&#39;s clinical findings that patients who are at high risk of thromboembolism can experience fewer strokes with AtriClip.The company expects significant growth potential for the use of mechanical appendage closure.</p>
<h2>More on the News</h2>
<p>The LAA is a major source of blood clots in patients with atrial fibrillation (Afib), and the AtriClip device series represents a novel approach to electrically isolate, exclude, and ultimately remove the LAA in the course of heart surgery.</p>
<p>More than 85 peer-reviewed papers on the short- and long-term safety and effectiveness of AtriClip devices have been published since the device initially went into use in 2007. This amounts to more than 11,000 patients who were investigated in various regions. The ArtiClip devices, which are already driving revenues in the United States, are likely to generate more international revenues after the expansion of the CE- Mark indication.</p>
<p>In July 2024, AtriCure announced that it had received regulatory approval from the&nbsp;National Medical Products Administration of&nbsp;China&nbsp;to market and sell several models of its AtriClip&nbsp;LAA Exclusion System.The company is likely to work closely with Chinese regulatory authorities to facilitate the introduction of additional innovative products in the future. This approval is expected to expand AtriCure&#39;s business globally and generate additional revenues.</p>
<h2>Industry Prospects</h2>
<p>Per a report by Grand View Research, the global atrial fibrillation market size&nbsp;was estimated to be $22.4 billion in 2022&nbsp;and is expected to witness a growth rate of 10.1% from 2023 to 2030.</p>
<p>The increasing prevalence of AFib and growing awareness about the condition are expected to drive the market. Factors such as the aging population, lifestyle changes, and the surge in chronic illnesses such as obesity and diabetes are contributing to the rising incidence of atrial fibrillation.</p>
<h2>Product Portfolio Expansion</h2>
<p>AtriCure, a leading innovator in surgical treatments and therapies for Afib, LAA management and post-operative pain management, boasts a strong product portfolio and plans to expand to improve patient care in the future.</p>
<p>In April, AtriCure launched the cryoSPHERE+&nbsp;cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure&#39;s legacy cryoSHPERE&nbsp;device. The cryoSPHERE+&nbsp;received FDA 510(k) clearance for temporarily blocking pain by ablating peripheral nerves in adult patients and by ablating intercostal nerves under direct visualization in adolescent patients.</p>
<p>The company is likely to advance several clinical initiatives in the second half of 2024, including its LeAAPS stroke reduction trial and introduce new products across its markets, with two cryoSPHERE probes to reduce freeze times and the most advanced, smallest profile AtriClip device.</p>
<h2>Price Performance</h2>
<p>In the year-to-date period, ATRC&#39;s shares have plunged 31.8% against the industry&#39;s rise of 9.1%. The S&amp;P 500 has gained 17.8% in the same time frame.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6c/75176.jpg?v=1020748899" /></p>
<p>Image Source: Zacks Investment Research</p>
<h2>Zacks Rank and Stocks to Consider</h2>
<p>ATRC carries a Zacks Rank #3 (Hold) at present.</p>
<p>Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service,&nbsp;Quest Diagnostics&nbsp;and&nbsp;ABM Industries. While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy).</p>
<p>Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.</p>
<p>Universal Health Service has gained 41.1% compared with the&nbsp;industry&#39;s&nbsp;34.8% rise so far this year.</p>
<p>Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.</p>
<p>Quest Diagnostics shares have gained 3.7% so far this year compared with the&nbsp;industry&#39;s&nbsp;10.2% rise.</p>
<p>ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.</p>
<p>ABM&#39;s shares have risen 24.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;11.9% growth.</p>
<p><a href="https://www.zacks.com/stock/news/2326561/atricure-s-atrc-atriclip-receives-expanded-ce-mark-indication?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2326561">To read this article on Zacks.com click here.</a></p>


Earnings

Earnings Beats

Small Cap

Markets

Analyst Ratings

Trading Ideas

AtriCure's AtriClip Receives Expanded CE-Mark Indication

AtriCure Receives Expanded Indication For AtriClip In Europe For High-Risk Thromboembolism Patients, Validating Its Effectiveness In Reducing Stroke Events During Cardiac Surgery

<p>Analysts' ratings for AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for AtriCure, presenting an average target of $37.17, a high estimate of $53.00, and a low estimate of $26.00. Experiencing a 16.47% decline, the current average is now lower than the previous average price target of $44.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722452497_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive AtriCure. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of AtriCure compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of AtriCure's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into AtriCure's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AtriCure analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About AtriCure</h2>
<p>AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.</p>
<h3>Financial Insights: AtriCure</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> AtriCure's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>16.43%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> AtriCure's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-12.19%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> AtriCure's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-2.88%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-2.2%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.17</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Navigating 6 Analyst Ratings For AtriCure

<p>BTIG  analyst Marie Thibault   maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and lowers the price target from $58 to $53.</p>


Price Target

BTIG Maintains Buy on AtriCure, Lowers Price Target to $53

<p>JP Morgan  analyst Robbie Marcus   maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Overweight and lowers the price target from $34 to $30.</p>


JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $30

<p>Stifel  analyst Rick Wise   maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and lowers the price target from $30 to $26.</p>


Stifel Maintains Buy on AtriCure, Lowers Price Target to $26

<p>Needham  analyst Mike Matson   maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and lowers the price target from $40 to $34.</p>


Needham Maintains Buy on AtriCure, Lowers Price Target to $34

<p>Piper Sandler  analyst Matt O'Brien   maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Overweight and lowers the price target from $65 to $40.</p>


Piper Sandler Maintains Overweight on AtriCure, Lowers Price Target to $40

<p>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) reported quarterly losses of $(0.17) per share which met the analyst consensus estimate.  The company reported quarterly sales of $116.30 million which beat the analyst consensus estimate of $116.18 million by 0.10 percent.  This is a 15.24 percent increase over sales of $100.92 million the same period last year.</p>


AtriCure Q2 2024 GAAP EPS $(0.17), Inline, Sales $116.30M Beat $116.18M Estimate

Health Care

AtriCure Receives National Medical Products Administration (NMPA) Approval To Sell AtriClip Devices in China

<p>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $40.17, with a high estimate of $49.00 and a low estimate of $32.00. A decline of 13.05% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1720465269_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of AtriCure among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$49.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$46.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AtriCure. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of AtriCure compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of AtriCure's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of AtriCure's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AtriCure analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About AtriCure</h2>
<p>AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.</p>
<h3>AtriCure's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> AtriCure's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>16.43%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> AtriCure's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-12.19%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> AtriCure's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-2.88%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-2.2%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.17</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings For AtriCure

<p>Needham  analyst Mike Matson   reiterates AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and maintains $40 price target.</p>


Reiteration

Needham Reiterates Buy on AtriCure, Maintains $40 Price Target

<h3>Gainers</h3>
<ul>
<li><strong>Mustang Bio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock moved upwards by 50.0% to $1.12 during Tuesday's regular session. The company's market cap stands at $31.7 million. </li>
<li><strong>Sonoma Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares increased by 27.95% to $0.22. The company's market cap stands at $3.3 million. The company's, Q4 earnings came out yesterday. </li>
<li><strong>Vaxart</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) shares moved upwards by 27.83% to $0.67. The market value of their outstanding shares is at $118.6 million. </li>
<li><strong>Silk Road Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILK#NASDAQ">SILK</a>) shares moved upwards by 23.92% to $26.86. The company's market cap stands at $1.0 billion. </li>
<li><strong>Kintara Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock rose 18.1% to $0.21. The company's market cap stands at $11.6 million. </li>
<li><strong>AtriCure</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) shares rose 16.01% to $23.04. The market value of their outstanding shares is at $1.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>DermTech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMTK#NASDAQ">DMTK</a>) shares decreased by 59.5% to $0.13 during Tuesday's regular session. The company's market cap stands at $4.7 million. </li>
<li><strong>Zentalis Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) shares declined by 35.7% to $5.39. The company's market cap stands at $383.1 million. </li>
<li><strong>Anitra</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) shares fell 30.21% to $0.16. The market value of their outstanding shares is at $4.6 million. </li>
<li><strong>Scinai Immunotherapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock decreased by 28.75% to $3.99. The market value of their outstanding shares is at $2.3 million. </li>
<li><strong>Taysha Gene Therapies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares decreased by 27.18% to $2.94. The market value of their outstanding shares is at $548.8 million. </li>
<li><strong>Autonomix Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock fell 26.67% to $0.99. The market value of their outstanding shares is at $18.6 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

AMIX

AZTR

DMTK

Kintara Therapeutics, Inc. - Common Stock

KTRA

MBIO

SCNI

SILK

SNOA

TSHA

VXRT

ZNTL

12 Health Care Stocks Moving In Tuesday's Intraday Session

Rumors

Watching AtriCure; Traders Circulating Unconfirmed Rumor Suggesting Edwards Lifesciences Is Said To Mull Takeover Bid For The Co

<p>Canaccord Genuity  analyst William Plovanic   maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and lowers the price target from $57 to $49.</p>


Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $49

WIIM

AtriCure shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results. Also, Needham and JP Morgan lowered their respective price targets on the stock.

<p>JP Morgan  analyst Robbie Marcus   maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Overweight and lowers the price target from $42 to $34.</p>


JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $34

<p>In the latest quarter, 6 analysts provided ratings for AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $44.0, along with a high estimate of $58.00 and a low estimate of $32.00. A 10.66% drop is evident in the current average compared to the previous average price target of $49.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714651277_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive AtriCure is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$42.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AtriCure compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of AtriCure's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of AtriCure's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AtriCure analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into AtriCure's Background</h2>
<p>AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.</p>
<h3>AtriCure's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, AtriCure showcased positive performance, achieving a revenue growth rate of <strong>21.03%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-9.19%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> AtriCure's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-2.11%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> AtriCure's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-1.61%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.16</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cracking The Code: Understanding Analyst Reviews For AtriCure

<p>Needham  analyst Mike Matson   maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and lowers the price target from $46 to $40.</p>


Needham Maintains Buy on AtriCure, Lowers Price Target to $40

AtriCure receives regulatory approval to sell AtriClip devices in China

AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care

Notable earnings after Tuesday's close

AtriCure Non-GAAP EPS of -$0.17 in-line, revenue of $116.3M beats by $0.12M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>AtriCure</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/atrc-stock-quote/"><strong>ATRC</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>AtriCure reported earnings per share of -17 cents. This met the analyst estimate for EPS of -17 cents.</li><li>The company reported revenue of $116.27 million.</li><li>This was 0.08% better than the analyst estimate for revenue of $116.18 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/07/atrc-stock-earnings-atricure-for-q2-of-2024/">ATRC Stock Earnings: AtriCure Meets EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ATRC Stock Earnings: AtriCure Meets EPS, Beats Revenue for Q2 2024

AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript

Atricure (ATRC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel Stauder from JMP Sec...

AtriCure's Growth Prospects and Buy Rating Despite Short-Term Challenges

Atricure (ATRC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst William Plovanic from Canac...

AtriCure's Resilience Amidst Competition: A Strong Buy Recommendation

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Incyte (INCY – Research Report), Atricure (ATRC – Re...

Analysts Are Bullish on These Healthcare Stocks: Incyte (INCY), Atricure (ATRC)

Piper Sandler Remains a Buy on Atricure (ATRC)

ACGL

AEIS

ANET

ATEN

ATOM

BGFV

BLKB

BOWFF

BRSP

CCCS

CHCT

DENN

INCY

MSFT

PINS

POWL

PRTS

QRVO

QUAD

RCKY

SBUX

SEMHF

SSNLF

STAG

SWKS

TIMB

TRTX

TRVG

UMBF

VOYA

WERN

WTTR

Press Releases

AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference

AtriCure Reports First Quarter 2024 Financial Results

AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference

AtriCure to Announce Second Quarter 2024 Financial Results

AtriCure Receives Regulatory Approval to Sell AtriClip® Devices in China

AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference

AtriCure Reports Second Quarter 2024 Financial Results

AtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial Fibrillation

AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device

Comments

AtriCure

Intérêt court

AtriCure (NASDAQ:ATRC) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL